Comparative Pharmacology
Head-to-head clinical analysis: DESMOPRESSIN ACETATE NEEDS NO REFRIGERATION versus NOCDURNA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESMOPRESSIN ACETATE NEEDS NO REFRIGERATION versus NOCDURNA.
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) vs NOCDURNA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic analog of vasopressin (antidiuretic hormone) that acts on V2 receptors in renal collecting ducts to increase water reabsorption, reducing urine output. Also transiently increases factor VIII and von Willebrand factor via V2 receptor activation on endothelium.
NOCDURNA (desmopressin) is a synthetic analog of vasopressin, an antidiuretic hormone. It acts on V2 receptors in the renal collecting ducts to increase water reabsorption, reducing urine production.
Central diabetes insipidus: 0.1-0.4 mL (10-40 mcg) intranasally once or twice daily. Nocturnal enuresis: 20-40 mcg intranasally at bedtime. IV dosing for central diabetes insipidus: 2-4 mcg once daily subcutaneously or intravenously.
50 mcg sublingual tablet once daily, 1 hour before bedtime.
None Documented
None Documented
Terminal elimination half-life: 2.8-3.6 hours (range 1.5-5 hours). Prolonged in renal impairment (up to 8-10 hours) and in infants.
~2.8 hours; short half-life suitable for nocturnal dosing with minimal morning carryover
Renal: >90% unchanged drug excreted in urine via glomerular filtration and tubular secretion. Fecal: negligible (<1%).
Renal: >80% as unchanged drug; fecal: ~10%
Category A/B
Category C
Vasopressin Analog
Vasopressin Analog